Inhibitory effect of EGFR antisense oligodeoxynucleotide on human hepatoma cell line

Hepatobiliary and Pancreatic Diseases International

Volumn 4, Issue 3, 2005, Pages 433-436

  Gong, Zhi Bing ^a,b   Liu, Jing Mei ^a,c   Li, You Ming ^a,b  

^a Zhejiang University School of Medicine ^*

^b ZHEJIANG UNIVERSITY   (China)

^c JIANGXI MEDICAL COLLEGE   (China)

Author keywords

Antisense; Epidermal growth factor receptor; Hepatoma; Oligodeoxynucleotide

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; EPIDERMAL GROWTH FACTOR RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; HEPATOMA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL DIVISION; CELL LINE, TUMOR; HUMANS; LIVER NEOPLASMS; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; OLIGONUCLEOTIDES, ANTISENSE; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 23944496191     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Yarden Y, Sliwkowski MX. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001;2:127-137.
2. Zwick E, Bange J, Ullrich A. Receptor tyrosine kinases as targets for anticancer drugs. Trend Mol Med 2002;8:17-23.
3. Lin SY, Makino K, Xia W, Matin A, Wen Y, Kwong KY, et al. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 2001;3:802-808.
4. Morimitsu Y, Hsia CC, Kojiro M, Tabor E. Nodules of less-differentiated tumor within or adjacent to hepatocellular carcinoma: relative expression of transforming growth factor-alpha and its receptor in the different areas of tumor. Hum Pathol 1995;26:1126-1132.
5. Yamaguchi K, Carr BI, Nalesnik MA. Concomitant and isolated expression of TGF-alpha and EGF-R in human hepatoma cells supports the hypothesis of autocrine, paracrine, and endocrine growth of human hepatoma. J Surg Oncol 1995;58:240-245.
6. Tanaka H. Immunohistochemical studies on epidermal growth factor receptor in hepatocellular carcinoma. Nippon Shokakibyo Gakkai Zasshi 1991;88:138-144.
7. Liu XJ, An W, Lei TG, Rong Y, Du GG. Regulatory effect of hepatic stimulator substance on the proliferation of human hepatoma cells. Sheng Li Xue Bao 1998;50:543-550.
8. Wang Q, Lin ZY, Feng XL. Alterations in metastatic properties of hepatocellular carcinoma cell following H-ras oncogene transfection. World J Gastroenterol 2001;7:335-339.
9. Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 11978;75:280-284.
10. Jens K. Antisense technologies improvement through novel chemical modifications. Eur J Biochem 2003;270:1628-1644.
11. Krozely P. Epidermal growth factor receptor tyrosine kinase inhibitors: evolving role in the treatment of solid tumors. Clin J Oncol Nurs 2004;8:163-169.
12. Matsuo M, Sakurai H, Saiki I. ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, shows antimetastatic activity using a hepatocellular carcinoma model. Mol Cancer Ther 2003;6:557-561.
13. Hopfner M, Sutter AP, Huether A, Schuppan D, Zeitz M, Scherubl H. Targeting the epidermal growth factor receptor by gefitinib for treatment of hepatocellular carcinoma. J Hepatol 2004;41:1008-1016.
14. Schiffer E, Housset C, Cacheux W, Wendum D, Desbois-Mouthon C, Rey C, et al. Gefitinib, an EGFR inhibitor, prevents hepatocellular carcinoma development in the rat liver with cirrhosis. Hepatology 2005;41:307-314.
15. Ensinger C, Spizzo G, Moser P, Tschoerner I, Prommegger R, Gabriel M, et al. Epidermal growth factor receptor as a novel therapeutic target in anaplastic thyroid carcinomas. Ann N Y Acad Sci 2004;1030:69-77.
16. Canil CM, Moore MJ, Winquist E, Baetz T, Pollak M, Chi KN, et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: A trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol 2005;23:455-460.
17. Kira S, Nakanishi T, Suemori S, Kitamoto M, Watanabe Y, Kajiyama G. Expression of transforming growth factor alpha and epidermal growth factor receptor in human hepatocellular carcinoma. Liver 1997;17:177-182.
18. Daveau M, Scotte M, Francois A, Coulouarn C, Ros G, Tallet Y, et al. Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Mol Carcinog 2003;36:130-141.
19. Fukusato T, Mori S, Kawamoto T, Taniguchi S, Machinami R. Immunohistochemical and ultrastructural localization of epidermal growth factor receptor in human liver and hepatocellular carcinoma tissues. Acta Pathol Jpn 1990;40:22-29.
20. Ito Y, Takeda T, Sakon M, Tsujimoto M, Higashiyama S, Noda K , et al. Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer 2001; 84:1377-1383.
21. Zhou XD. Recurrence and metastasis of hepatocellular carcinoma: progress and prospects. Hepatobiliary Pancreat Dis Int 2002;1:35-41.
22. Zhao YN, Cao J, Wu FX, Ou C, Yuan WP, Mo QG , et al. Expression and significance of EGF mRNA and EGFR mRNA in hepatocellular carcinoma. Ai Zheng 2004;7:762-766.